Oteracil potassium


Full Prescribing Info
Dosage/Direction for Use

Oral
Resectable gastric carcinoma
Adult: In combination with tegafur and gimeracil: 40 mg/m2 bid for 7 days pre-operatively and for 15 days after operation starting on day 15 after operation.
Action
Oteracil potassium is used as part of an antineoplastic combination product that includes tegafur and gimeracil. Oteracil inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate and possibly reduces 5-FU induced GI adverse effects.
Disclaimer: This information is independently developed by CIMS based on oteracil potassium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in